ACS Medicinal Chemistry Letters · 2011 · 46 citations · 22 references
MedicineMedicinal ChemistryPharmacologyGastrointestinal PharmacotherapyMolecular PharmacologyPharmacodynamicsAnti-inflammatory PharmacologyGastrointestinal PharmacologyInflammatory Bowel DiseaseReceptor PharmacologyAdenosine Receptor Agonist TherapyAdenosine Receptor SignalingEx Vivo ModelsInflammatory Bowel Disease TherapySystemic Adverse Effects
Adenosine A2A receptor agonists for the local treatment of inflammatory bowel disease (IBS) were designed and synthesized. Polar groups were introduced to prevent peroral absorption and subsequent systemic, e.g., hypotensive, side effects. 4-(2-{6-Amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-2-ylthio}ethyl)benzenesulfonic acid (7, PSB-0777) was selected for further evaluation in rat ileum/jejunum preparations in ex vivo experiments. Compound 7 significantly improved impaired acetylcholine-induced contractions induced by 2,4,6-trinitrobenzenesulfonic acid and showed synergism with an A2B-selective antagonist. Thus, nonabsorbable, locally active A2A agonists, as a monotherapy or in combination with an A2B antagonist, may be an efficient novel treatment for IBS, preventing the severe systemic side effects of known A2A agonists.
22
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation
Guillaume Lebon, Tony Warne, Patricia C. Edwards et al. · Nature · 2011 · 883 citations · Full text
Structure of an Agonist-Bound Human A <sub>2A</sub> Adenosine Receptor
Fei Xu, Huixian Wu, Vsevolod Katritch et al. · Science · 2011 · 814 citations